Interim OS Analysis Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab vs Keytruda in PD-L1+ve Advanced NSCLC from HARMONi-2 Study April 30, 2025
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Ph 2b SunRISe-1 study (Cohort 2) in NMIBC patients April 22, 2025
Enhertu + pertuzumab in DESTINY-Breast09 Ph 3 trial demonstrated PFS improvement in vs THP as a 1L treatment for patients with HER2-positive metastatic breast cancer April 22, 2025
Preliminary results from Ph 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma announced April 22, 2025
Ph 2 study of Bria-IMT + CPI outperforms ADC drugs in HR+ metastatic breast cancer (MBC) patients April 22, 2025
Trodelvy + Keytruda Demonstrated PFS Improvement in Patients With Previously Untreated PD-L1+ Metastatic TNBC April 22, 2025
Ph 3 DeLLphi-304 trial of IMDELLTRA (tarlatamab-dlle) in SCLC patients met primary endpoint at a planned interim analysis April 16, 2025
SON-1010 + Atezolizumab combo Demonstrates a Strong Safety Profile in Platinum-Resistant Ovarian Cancer patients April 15, 2025
Tovecimig (CTX-009) Meets Primary Endpoint in Ph 2/3 Study in Patients with Biliary Tract Cancer April 8, 2025
Preliminary positive immune response data announced from Ph 3 clinical trial FLAMINGO-01 of GLSI-100 April 8, 2025
SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer April 8, 2025
SC Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior PK Compared to IV KEYTRUDA in Pivotal 3475A-D77 Trial April 2, 2025
FAILED TRIAL: Ph 3 ARTISTRY-7 Trial of Nemvaleukin + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer did not achieve a statistically significant improvement in OS April 2, 2025
Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer April 2, 2025
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) outperform osimertinib with a significant OS benefit in patients with EGFR-mutated NSCLC April 2, 2025
In LAURA Ph 3 trial, Tagrisso continues to demonstrate improved OS trend in unresectable, Stage III setting April 2, 2025
75.5% CR at any time in Ph 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) April 2, 2025
Both Prolonged Median OS and Long Tail of Survival in Ph 2a Trial of CAN-2409 in Advanced NSCLC Patients Non-Responsive to ICI Treatment Reported April 2, 2025
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment March 26, 2025
